A new intragastric delivery system for the treatment of Helicobacter pylori associated gastric ulcer: In vitro evaluation

Journal of Controlled Release

Volumn 57, Issue 3, 1999, Pages 215-222

  Yang, Libo ^a   Eshraghi, Jamshid ^b   Fassihi, Reza ^a  

^a TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

^b UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

Controlled drug release; Intragastric drug delivery; Tetracycline and metronidazole; Treatment of Helicobacter pylori; Triple therapy

Indexed keywords

BISMUTH SALT; EXCIPIENT; HYDROXYPROPYLMETHYLCELLULOSE; MACROGOL; METRONIDAZOLE; TETRACYCLINE;

ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; HELICOBACTER PYLORI; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PEPTIC ULCER; PRIORITY JOURNAL; TABLET;

ALGORITHMS; ANTACIDS; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; BISMUTH; DRUG COMBINATIONS; DRUG DELIVERY SYSTEMS; HELICOBACTER INFECTIONS; METRONIDAZOLE; SOLUBILITY; STOMACH ULCER; TABLETS, ENTERIC-COATED; TETRACYCLINE;

EID: 0033046507     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(98)00066-2     Document Type: Article

References (28)

1. Graham D.Y. Nonsteroidal anti-inflammatory drugs, Helicobacter pylori and ulcers: where we stand. Am. J. Gastroenterol. 91:1996;2080-2086.
2. Rune S.J. History of Helicobacter pylori infection. Scand. J. Gastroenterol. 31(Suppl. 214):1996;2-4.
3. Blum A.L. Helicobacter pylori and peptic ulcer disease. Scand. J. Gastroenterol. 31(Suppl. 214):1996;24-27.
4. Logan R.P.H. Helicobacter pylori and gastric cancer. Lancet. 344:1994;1078-1079.
5. Inouye H., Yamamoto I., Tanida N.et al. Campylobacter pylori in Japan: bacteriological fracture and prevalence in healthy subjects and patients with gastroduodenal disorders. Gastroenterol. Jpn. 24:1989;494-504.
6. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer disease, Helicobacter pylori in Peptic Ulcer Disease. JAMA 272 (1994) 65-69.
7. Marshall B.J., Warren J.R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1:1984;1311-1315.
8. Lee A. The nature of Helicobacter pylori. Scand. J. Gastroenterol. 31(Suppl. 214):1996;5-8.
9. Tytgat G.N. Current indications for Helicobacter pylori eradication therapy. Scand. J. Gastroenterol. 31(Suppl. 215):1996;70-73.
10. Cooreman M.P., Krausgrill P., Hengels K.J. Local gastric and serum amoxicillin concentrations after different oral application forms. Antimicrob. Agents Chemother. 37:1993;1506-1509.
11. Gold B.D., Huesca M., Sherman P.M.et al. Helicobacter mustelae and Helicobacter pylori bind to common lipid receptors in vitro. Infect. Immun. 61:1993;2632-2638.
12. Slomiany B.L., Piotrowski J., Samanta A.et al. Campylobacter pylori colonization factors shows specificity for lactosylceramide sulfate and GM3 ganglioside. Biochem. Internat. 19:1989;929-936.
13. Borén T., Falk P., Roth K.A.et al. Attachment of Helicobacter pylori to human gastric epithelium mediated by blood group antigens. Science. 262:1993;1892-1895.
14. D.H. Balaban, D.A. Peura, Helicobacter pylori-associated peptic ulcer and gastritis, in: J.T. LaMont (Ed.), Gastrointestinal Infections, Diagnosis and Management, Marcel Dekker, New York, 1997, pp. 29-69.
15. Marshall B.J., Barrett L.J., Prakash C.et al. Urea protects Helicobacter (Campylobacter) pylori from the bactericidal effect of acid. Gastroenterology. 99:1990;697-702.
16. triebling A.T., Korsten M.A., Dlugosz J.W.et al. Severity of Helicobacter-induced gastrci injury correlates with gastric juice ammonia. Dig. Dis. Sci. 36:1991;1089-1096.
17. Tytgat G.N.J. Treatments that impact favorably upon the eradication of Helicobacter pylori and ulcer recurrence. Aliment. Pharmacol. Ther. 8:1994;359-368.
18. Heatley R.V. The treatment of Helicobacter pylori infection. Aliment. Pharmacol. Ther. 6:1992;291-303.
19. Axon A.T.R. Helicobacter pylori therapy: effect on peptic ulcer disease. J. Gastroenterol. Hepatol. 6:1991;131-137.
20. Ingani H.M., Timmermans J., Moës A.J. Conception and in vivo investigation of peroral sustained release floating dosage forms with enhanced gastrointestinal transit. Int. J. Pharm. 35:1987;157-164.
21. Timmermans J., Moës A.J. Factors controlling the buoyancy and gastric retention capabilities of floating matrix capsules: new data for reconsidering the controversy. J. Pharm. Sci. 83:1994;18-24.
22. Erni W., Held K. The hydrodynamically balanced system: a novel principle of controlled drug release. Eur. Neurol. 27:1987;21-27.
23. Moës A.J. Gastroretentive dosage forms. Crit. Rev. Ther. Drug Del. Syst. 10:1993;143-195.
24. Yang L.-B., Fassihi R.A. Zero-order release kinetics from a self-correcting floatable asymmetric configuration drug delivery system. J. Pharm. Sci. 85:1996;170-173.
25. R. Fassihi, L. Yang, US Patent 5,783,212, July, 21 (1998).
26. Harland R.S., Gazzaniga A., Sangalli M.E.et al. Drug/polymer matrix swelling and dissolution. Pharm. Res. 5:1988;488-494.
27. Pham A.T., Lee P.I. Probing the mechanism of drug release from hydroxypropylmethyl cellulose matrics. Pharm. Res. 11:1994;1379-1384.
28. Yang L.-B., Fassihi R. Examination of drug solubility, polymer type, hydrodynamics and loading dose on drug release behavior from a triple-layer asymmetric configuration delivery system. Int. J. Pharm. 155:1997;219-229.